At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MURA Mural Oncology
Halted 12-11 14:47:20 EST
2.04
+0.00
0.00%
High2.04Low2.04Vol0.00
Open2.04D1 Closing2.04Amplitude0.00%
Mkt Cap35.38MTradable Cap28.64MTotal Shares17.34M
T/O259.92KT/O Rate0.00%Tradable Shares14.04M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

XOMA Royalty Completes Acquisition of Mural Oncology
MT Newswires Live  ·  12-05
XOMA Royalty Completes Acquisition of Mural Oncology
Press Release: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
Dow Jones  ·  12-05
Press Release: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters  ·  12-05
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Press Release: Mural Oncology Announces Sanction of the Scheme by the High Court
Dow Jones  ·  12-04
Press Release: Mural Oncology Announces Sanction of the Scheme by the High Court
Mural Oncology Sets Final Cash Consideration at $2.035 Per Share in XOMA Royalty Acquisition
Reuters  ·  11-26
Mural Oncology Sets Final Cash Consideration at $2.035 Per Share in XOMA Royalty Acquisition
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
THOMSON REUTERS  ·  11-26
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
Mural Oncology Plc - Total Cash Consideration of $2.035 per Share
THOMSON REUTERS  ·  11-26
Mural Oncology Plc - Total Cash Consideration of $2.035 per Share
Mural Oncology Approves Acquisition by XRA 5 Corp.
TIPRANKS  ·  10-25
Mural Oncology Approves Acquisition by XRA 5 Corp.
Mural Oncology shareholders approve acquisition by XRA 5 Corp.
TIPRANKS  ·  10-25
Mural Oncology shareholders approve acquisition by XRA 5 Corp.
Mural Oncology plc Held Shareholder Meeting
Reuters  ·  10-25
Mural Oncology plc Held Shareholder Meeting
Press Release: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Dow Jones  ·  10-25
Press Release: Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Mural Oncology plc Announces Date for Shareholder Scheme Meeting
Reuters  ·  09-24
Mural Oncology plc Announces Date for Shareholder Scheme Meeting
Press Release: Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Dow Jones  ·  09-24
Press Release: Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
Mural Oncology Plc Announces Acquisition by XOMA Royalty Corporation
TIPRANKS  ·  09-24
Mural Oncology Plc Announces Acquisition by XOMA Royalty Corporation
Mural Oncology plc Files Initial Statement of Beneficial Ownership; Trium Capital LLP Named as 10% Owner
Reuters  ·  09-02
Mural Oncology plc Files Initial Statement of Beneficial Ownership; Trium Capital LLP Named as 10% Owner
Mural Oncology Announces Agreement to be Acquired by XOMA Royalty for Cash Consideration
Reuters  ·  08-20
Mural Oncology Announces Agreement to be Acquired by XOMA Royalty for Cash Consideration
Mural Oncology Announces Entry Into Agreement to Be Acquired by Xra 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty for Between $2.035 and $2.24 in Cash per Share
THOMSON REUTERS  ·  08-20
Mural Oncology Announces Entry Into Agreement to Be Acquired by Xra 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty for Between $2.035 and $2.24 in Cash per Share
Mural Oncology Plc - Acquisition Values Mural at About $36.2 Mln
THOMSON REUTERS  ·  08-20
Mural Oncology Plc - Acquisition Values Mural at About $36.2 Mln
Mural Oncology Q2 EPS $(2.78) Misses $(1.51) Estimate
Benzinga  ·  08-04
Mural Oncology Q2 EPS $(2.78) Misses $(1.51) Estimate
Mural Oncology Reports Q2 2025 Net Loss of $48 Million, Up from $31.6 Million in Q2 2024 Due to Restructuring Charges
Reuters  ·  08-04
Mural Oncology Reports Q2 2025 Net Loss of $48 Million, Up from $31.6 Million in Q2 2024 Due to Restructuring Charges

Introduction

Company Name.
Mural Oncology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
Issue price:
--